Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0025663,
umls-concept:C0079043,
umls-concept:C0134499,
umls-concept:C0205307,
umls-concept:C0242896,
umls-concept:C0681850,
umls-concept:C1280500,
umls-concept:C1512045,
umls-concept:C1545588,
umls-concept:C1550501,
umls-concept:C1706203,
umls-concept:C1999230,
umls-concept:C2349001,
umls-concept:C2697811
|
pubmed:issue |
4
|
pubmed:dateCreated |
1994-8-15
|
pubmed:abstractText |
To study whether it would be possible to assess anticholinergic drugs in normal subjects with histamine-(HIST) induced bronchoconstriction, three doses of oxitropium bromide (100, 200 and 400 micrograms) was inhaled in random order by twelve normal volunteers in a single-blind, placebo-controlled study. Dose response slope [DRS = maximal percentual fall in pulmonary function/maximal noncumulative histamine dose (mumol)] was used as an index of bronchial reactivity, and was calculated for FEV1 (DRSFEV1) and area under the flow-volume curve (DRSAEFV). The bronchial reactivity and its reproducibility was first tested with a standard provocation method. An abbreviated, single-dose, method was used in the measurement of the effects of oxitropium. The reproducibility of HIST-provocations were good with intraclass correlations of 0.97 and 0.99 for logDRSFEV1 and logDRSAEFV, respectively. However, DRSAEFV seemed to be better in this respect as DRSFEV1. Also, the single-dose method gave results that were comparable to the standard one. The largest dose of oxitropium diminished the median DRS from 2.6 to 0.01 and from 5.2 to -0.2 for FEV1 and AEFV, respectively. All oxitropium doses differed significantly from placebo (P < 0.01) and from each other (P < 0.05) with DRSAEFV-values, but when DRSFEV1 was used, a significant difference was detected only between placebo and active treatment (P < 0.01). In conclusion, since the vagal mechanisms seem to be the predominant system mediating HIST-induced bronchoconstriction in normal subjects, it is possible with DRSAEFV to evaluate the efficacy of anticholinergics against HIST-induced bronchoconstriction in these subjects.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0954-6111
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
88
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
273-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8036289-Adult,
pubmed-meshheading:8036289-Bronchial Provocation Tests,
pubmed-meshheading:8036289-Bronchoconstriction,
pubmed-meshheading:8036289-Dose-Response Relationship, Drug,
pubmed-meshheading:8036289-Female,
pubmed-meshheading:8036289-Histamine,
pubmed-meshheading:8036289-Humans,
pubmed-meshheading:8036289-Male,
pubmed-meshheading:8036289-Parasympatholytics,
pubmed-meshheading:8036289-Random Allocation,
pubmed-meshheading:8036289-Scopolamine Derivatives,
pubmed-meshheading:8036289-Single-Blind Method
|
pubmed:year |
1994
|
pubmed:articleTitle |
A method for measuring the effects of anticholinergics on histamine-induced bronchoconstriction in normal subjects. Oxitropium bromide provides dose-dependent protection.
|
pubmed:affiliation |
Department of Clinical Pharmacology, University of Turku, Finland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|